Opendata, web and dolomites

IF-EBOla SIGNED

Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IF-EBOla project word cloud

Explore the words cloud of the IF-EBOla project. It provides you a very rough idea of what is the project "IF-EBOla" about.

story    antibodies    effect    patients    period    leone    ec    follow    critical    outbreak    qualified    diagnosed    emergency    self    virus    obligated    levels    action    transcriptomes    generate    detection    understand    revisited    mainly    antibody    validated    once    mds    usdep    quality    equine    spreading    ema    strategically    innovative    if    complementary    preparation    contacts    survivors    sites    site    experts    therapy    diversity    public    rules    evd    initial    treatment    evolution    authorizations    capacity    ebov    ebola    experimental    designed    phases    sierra    microorganisms    mortality    scientific    form    ethical    homeostatic    convalescents    diagnostics    sequencing    pathology    save    officer    ab    passive    data    infectious    cured    preclinical    reduce    absence    health    regulatory    polyclonal    prepare    originally    horse    homeostasis    outstanding    beginning    ultrasensitive    dna    therapeutic    carry    accurate    unforeseen    metagenomics    cure    validation    neutralizing    consisting    arrays    profiling    convalescent    profile    diagnostic    pernicious    viremia    organization    liberia    extend    ngs    2010    immune    technological    individuals    sharing    anti    clinical    safe    epidemic    lives    modify    status    foreseen    actions    companies   

Project "IF-EBOla" data sheet

The following table provides information about the project.

Coordinator
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT 

Organization address
address: BOULEVARD DE DUNKERQUE 44 CS 90009
city: MARSEILLE
postcode: 13572
website: www.ird.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://infightebola.eu/
 Total cost 2˙037˙770 €
 EC max contribution 1˙992˙770 € (98%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
 Code Call H2020-Adhoc-2014-20
 Funding Scheme RIA
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT FR (MARSEILLE) coordinator 360˙895.00
2    FABENTECH FR (LYON) participant 972˙750.00
3    BEN-GURION UNIVERSITY OF THE NEGEV IL (BEER SHEVA) participant 199˙350.00
4    ORION INTEGRATED BIOSCIENCES INC. US (NEW ROCHELLE) participant 135˙000.00
5    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 127˙075.00
6    METABIOTA INC US (SAN FRANCISCO) participant 100˙000.00
7    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 52˙700.00
8    ABSISKEY FR (ANGERS) participant 45˙000.00
9    ABSISKEY CP FR (GRENOBLE) participant 0.00
10    UNIVERSITY OF MANITOBA CA (MANITOBA) participant 0.00

Map

 Project objective

IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal. The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives.

We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this “non-emergency” period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (“pathology”) profiling of patients and survivors. Originally (“emergency period”) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story “USDEP” project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics).

 Deliverables

List of deliverables.
Whole infectious profiles Documents, reports 2019-10-29 14:07:31
Ebola virus diversity assessed by sequencing Documents, reports 2019-10-28 17:21:42
Ethical regulations, security and safety set up for diagnostic and follow-up of patients of the phase 1 (without treatment) Documents, reports 2019-10-28 17:21:42
Creation of the specific website of the project Websites, patent fillings, videos etc. 2019-10-28 17:21:42

Take a look to the deliverables list in detail:  detailed list of IF-EBOla deliverables.

 Publications

year authors and title journal last update
List of publications.
2015 W. Valdivia, D. Sheoran, & F. Veas
Ebola virus Genomic and Metagenomic signature Analyses of the 2014-15 West African Outbreak
published pages: , ISSN: , DOI:
7th Filovirus Conference 2019-10-28
2017 Aly Shamseddin, Céline Crauste, Erwann Durand, Pierre Villeneuve, Gregor Dubois, Thierry Durand, Joseph Vercauteren, Francisco Veas
Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions
published pages: 1700171, ISSN: 1438-7697, DOI: 10.1002/ejlt.201700171
European Journal of Lipid Science and Technology 119/11 2019-10-28
2017 F.Veas
Efficiency of innovative preparedness IF-EBOLA technologies: Ultrasensitive diagnostics, horse anti-Ebola virus polyclonal Fabs & metagenomic analyses of Ebola variants and co-infections
published pages: , ISSN: , DOI:
2019-10-28
2017 Y. Eskira A Sobarzo, F Veas L Lobel
Atypical immune response of EVD Long-term survivors
published pages: , ISSN: , DOI:
2019-10-28
2015 W. Valdivia-, D. Sheoran, G. Dubois, S. Tigrett, F. Veas
Metagenomic analyses and genomic fingerprint of co-infections of the EBOLA viral disease
published pages: , ISSN: , DOI:
2019-10-28
2015 C. Herbreteau & IF Ebola
Development of a specific polyclonal immunoglobulin against Ebola
published pages: , ISSN: , DOI:
2019-10-28
2015 F.Veas
Multi-technological platforms to solve unmet needs for rapid and efficient management of emerging diseases
published pages: , ISSN: , DOI:
2019-10-28
2017 M. Denizot, T. Racine, D. Pannetier, A. Pasquier, H. Raoul, JF Saluzzo, G. Kobinger, F. Veas, C. Herbreteau
Specific polyclonal F(ab’)2immunoglobulin fragments; in vitro characterization and in vivo effectiveness in post-exposure treatment against Zaire Ebola virus in mice
published pages: , ISSN: , DOI:
2019-10-28
2018 A Shamseddin, C Crauste, E Durand, P Villeneuve, G Dubois, T Pavlickova, Th Durand, J. Vercauteren, and F Veas
Resveratrol-Linoleate protects from exacerbated endothelial permeability via a drastic inhibition of the MMP-9 activity
published pages: , ISSN: , DOI:
2019-10-28
2017 R Metrop, JF Saluzzo, F Veas, C. Herbreteau
Lessons Learned from the Development of an Ebola Immunotherapy
published pages: , ISSN: , DOI:
2019-10-28
2017 S Tigrett, L Lobel, F Veas
A Universal virus capture method leading to a rapid and ultrasensitive detection of pathogens for early & late post-exposure countermeasures
published pages: , ISSN: , DOI:
2019-10-28
2015 W. Valdivia, D. Sheoran & F. Veas
RIGEL as a Powerful Computational Architecture for Genomic & Metagenomic Signature Discrimination: Analysis of the 2014-15 West African EBOLA Outbreak”
published pages: March 8-13, 2015, ISSN: , DOI:
Gordon Research Conferences, on 2019-10-28
2016 F.Veas
The preparedness IF-EBOLA toolbox for rapid and efficient mitigation of upcoming outbreaks. A platform model for emerging diseases
published pages: , ISSN: , DOI:
2019-10-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IF-EBOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IF-EBOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.)

BFHA 2020 (2019)

Innovation for better ageing

Read More  

VHFMoDRAD (2019)

Viral Haemorrhagic Fever: Modern Approaches for developing bedside Rapid Diagnostics

Read More  

eHealth Week (2016)

eHealth Week 2016

Read More